Zhongao Biomedical Technology

Zhongao Biomedical Technology (Guangdong) Co., Ltd. is a clinical-stage biopharmaceutical company established by overseas Chinese scientists. The firm focuses on developing innovative peptide drugs and therapies for diseases linked to the human papillomavirus (HPV), as well as various malignant tumors such as skin, cervical, and liver cancer. The company's strategic vision is to translate leading global research in HPV, immunotherapy, and peptide technology into marketable treatments.

The company was founded by Dr. Xiaosong Liu, who serves as the Chairman. Dr. Liu holds a clinical medicine doctorate from West China Hospital, Sichuan University, and was a doctoral candidate under Dr. Jian Zhou and Professor Ian Frazer, the co-inventors of the world's first cancer vaccine, Merck's HPV vaccine Gardasil. Since 1998, he has been engaged in HPV immunology and pathogenesis research at the University of Queensland in Australia. The core team also includes Chief Scientist Dr. Tianfang Wang, an expert in proteomics and peptidomics, and General Manager Dr. Guoying Ni, who has over a decade of experience in tumor microenvironment and immunotherapy research. Notably, Professor Ian Frazer, a co-inventor of the cervical cancer vaccine, is a shareholder and scientific advisor, providing significant strategic guidance.

Zhongao Biomedical operates through the development and commercialization of its proprietary drug pipeline. The company has developed a peptide platform capable of inducing pyroptosis (a form of inflammatory cell death) in cancer and virus-infected cells, which also activates tumor-associated macrophages to improve the tumor microenvironment. This platform is the foundation for multiple anti-tumor and anti-viral drug candidates. A key product in their pipeline is the ZA001 F1F3 ointment, a topical drug for treating HPV-induced condyloma acuminata (genital warts). In early 2025, this drug received clinical trial approval from the National Medical Products Administration in China. Pre-clinical studies suggest ZA001 has a dual mechanism of inducing pyroptosis in HPV-infected cells and activating an immune response. The company is also developing ZA001 as an injection for broad-spectrum anti-tumor applications and as a radionuclide-coupled drug. Another area of development is a therapeutic vaccine platform that enhances anti-tumor effects by combining a tumor antigen and an adjuvant with an IL-10 receptor inhibitor.

Keywords: biopharmaceutical, drug development, peptide drugs, HPV therapy, oncology, immunotherapy, cervical cancer, skin cancer, pyroptosis, tumor microenvironment, therapeutic vaccines, clinical trials, ZA001, innovative medicine, drug research, life sciences, biotechnology, condyloma acuminata, radionuclide drugs, molecular medicine